Investors
Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Erik Manting
Chief Executive Officer
About:
Dr Erik Manting (born 1971, Dutch) has worked for a number of years as a post-doctoral researcher in the field of immunology before making a career switch to banking in 2001. He has more than 15 years of experience in different commercial and management roles in banking, including five years as Executive Director Corporate Finance at Kempen & Co. He acted as CEO of DCPrime BV since March 2018 and was appointed as CEO of Immunicum AB in March 2021, following the merger between both companies in December 2020. The combined company was renamed Mendus in June 2022. Erik holds a MSc in Medical Biology and a PhD in Molecular Microbiology from the University of Groningen.
Ongoing engagements:
Supervisory board member (Chairman) Synerkine Pharma BV and Independent Director Transcode Therapeutics Inc.
Shares:
277,695
Stock options:
662,666 (LTI 2023/2027)
Alex Karlsson-Parra
Chief Scientific Officer
About:
Dr Alex Karlsson-Parra (MD) (born 1950, Swedish) was trained as physician in clinical immunology at Uppsala University Hospital, Uppsala, Sweden and has more than 20 years of experience in the field of transplantation immunology. In addition to his position as Co-Founder and CSO at Mendus, he has also served as Associate Professor in Clinical Immunology at Uppsala University Hospital, with special expertise in transplantation immunology and cancer immunotherapy and is former chairman of the Swedish Expert Group for Clinical Immunology. In 2014, Alex was awarded the Athena Prize, the most prestigious award for clinical research in the Swedish healthcare community. Prior to his current positions, he served as Associate Professor and Senior Physician at the Department of Clinical Immunology at Sahlgrenska University Hospital, Gothenburg, Sweden and Uppsala University Hospital, Sweden. Alex has been founder and CSO of Immunicum since 2002 and remained CSO after the merger with DCPrime in December 2020, to form Mendus. Alex holds a MD degree and PhD in Experimental and Clinical Immunology from Uppsala University, Sweden.
Ongoing engagements:
–
Shares: 39,124 (private and through related persons’ holdings)
Stock options: 189,333 (LTI 2023/2027)
Jeroen Rovers
Chief Medical Officer
About:
Dr Jeroen Rovers (MD) (born 1970, Dutch) was trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 20 years he worked in different academic institutes and companies, such as Wyeth and Organon and Kiadis Pharma, where he held the role as Chief Medical Officer. He has mainly worked on the development of products related to oncology, haematology and transplantation. Jeroen has acted as CMO of DCPrime BV since October 2018 and was appointed as CMO of Immunicum AB in March 2021, following the merger between both companies to form Mendus. Jeroen holds a MD degree and a PhD in Surgical Oncology from Leiden University.
Ongoing engagements:
–
Shares: 107,526
Stock options: 331,333 (LTI 2023/2027)
Lotta Ferm
Chief Financial Officer
About:
Lotta Ferm (born 1966, Swedish) has nearly 30 years of finance and controlling experience from a range of corporations including most recently Doktor24 Healthcare AB and Medivir AB in the healthcare and life science sectors. She has held CFO, Head of Finance and Head of Controlling positions consistently over the last decade and led the corporate finance and accounting functions for multiple transitions for dynamic and innovative companies. Lotta joined Mendus as CFO in October 2021. Lotta holds a degree in Business Administration and Economics from Högskolan Kristianstad and Växjö University.
Ongoing engagements:
–
Shares: 135,000 (private and through related persons’ holdings)
Stock options: 331,333 (LTI 2023/2027)
Leopold Bertea
Chief Technology Officer
About:
Dr Leopold Bertea (born 1964, French & Swiss) joined Mendus in May 2022. Before Mendus, he worked at Cellectis, a clinical-stage biotechnology company using a proprietary gene-editing platform to develop cell and gene therapies, where he most recently held the position of Senior Vice President Technical Operations Europe and was Member of the Executive Committee. With previous senior roles at Novartis, LFB Biotechnologies, and LFB’s subsidiary CELLforCURE, Sanofi, and Ciba-Geigy, Leopold brings a total of 30 years of biopharmaceutical industry experience to Mendus. Leopold holds a MSc and PhD in Chemical Engineering from ETH Zürich.
Ongoing engagements: –
Shares: 60,269
Stock options: 331,333 (LTI 2023/2027)